Our strategy is to be the leader in the development of pluripotent stem cell-based technologies and to apply those new technologies in the treatment of diseases that afflict large numbers of people worldwide. Our technical focus is in three areas of regenerative medicine: stem cells; hydrogel-based biomaterials for the culture and delivery of therapeutic cells; the core technologies needed to culture, differentiate and manufacture stem cells, and; the use of our stem cell-based knowledge for the development of cancer diagnostics.
Technology to direct clinical-grade human embryonic stem cells to become cells for the treatment of degenerative disease. PureStem Technology to derive clonally pure, unique PureStem embryonic progenitors providing scalable cultures to produce therapeutic cells free of potentially hazardous pluripotent stem cells.
BioTime's HyStem hydrogel technology is based on a unique chemical cross-linking strategy to prepare hyaluronan based hydrogels from chemically modified hyaluronan and other constituents. The result is a biomaterial that mimics the natural extra-cellular matrix environment in which cells live. These materials have applications in therapeutic cell delivery, delivery vehicles for bioactive molecules, 3-D cell culture, stem cell differentiation and tissue engineering.
BioTime and its family of companies employ deep knowledge and skill in various cell culture and manufacturing technologies. Stem cell derivation, culture, expansion, differentiation and manufacturing must be done in a manner that is acceptable under strict quality control standards. The end product must be free from exposure to non-human biological materials, must pass rigorous functional and safety tests and must be packaged in a manner that allows ease of storage, transport and patient application to be acceptable for use in humans.